VA
WST icon

Vident Advisory’s West Pharmaceutical WST Stock Holding History

Vident Advisory’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.9M Sell
43,604
-10,091
-19% -$2.51M 0.09% 192
2025
Q4 		$14.8M Sell
53,695
-363
-0.7% -$99.3K 0.13% 137
2025
Q3 		$14.2M Buy
54,058
+1,991
+4% +$484K 0.14% 142
2025
Q2 		$11.4M Buy
52,067
+49,039
+1,620% +$10.5M 0.13% 148
2025
Q1 		$678K Buy
3,028
+643
+27% +$177K 0.01% 878
2024
Q4 		$781K Buy
2,385
+484
+25% +$152K 0.01% 746
2024
Q3 		$571K Sell
1,901
-9,881
-84% -$3.03M 0.01% 858
2024
Q2 		$3.88M Buy
11,782
+2,271
+24% +$803K 0.11% 189
2024
Q1 		$3.76M Buy
9,511
+7,835
+467% +$2.9M 0.08% 252
2023
Q4 		$590K Buy
1,676
+12
+0.7% +$4.25K 0.01% 716
2023
Q3 		$624K Buy
+1,664
New +$644K 0.02% 640

Other funds holding WST

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vident Advisory's WST Position: Q1 2026 in Review

Vident Advisory reduced its West Pharmaceutical (WST) stake by 19% in Q1 2026, selling an estimated $2.51M and leaving 43,604 shares worth $10.9M. The position accounts for 0.09% of the portfolio, ranked #192.

Vident Advisory first reported a position in WST in Q3 2023 and has held it in 11 quarters since. The position peaked at $14.8M in Q4 2025. 753 funds tracked by Wall St. Rank hold WST as of Q1 2026.

  • Vident Advisory held 43,604 shares of West Pharmaceutical worth $10.9M as of Q1 2026.
  • Vident Advisory sold 10,091 West Pharmaceutical shares in Q1 2026, an estimated $2.51M.
  • West Pharmaceutical made up 0.09% of Vident Advisory's portfolio in Q1 2026, its #192 holding.
  • Vident Advisory first reported a position in West Pharmaceutical in Q3 2023 and has held it in 11 quarters since.
  • Vident Advisory's West Pharmaceutical position peaked at $14.8M in Q4 2025.
  • 753 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2026.

Based on Vident Advisory's 13F filing for Q1 2026, filed 15 May 2026.